Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018
HOUSTON, Dec. 06, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug
HOUSTON, Dec. 06, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces Breakthrough Discovery for its WP1066
WP1066 shown to counteract resistance to checkpoint blockades HOUSTON, Dec. 04, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which...
Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer
WP1732 shown to accumulate beneficially in pancreas HOUSTON, Nov. 28, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based...
Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug
Testing confirms ability of WP1732 to target pancreatic cancer HOUSTON, Nov. 15, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of...
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018
HOUSTON, Nov. 13, 2018 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122
Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, Nov. 08, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development...
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON, Nov. 01, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug...
Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
HOUSTON, Oct. 25, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas...
Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors
Data to be Presented at Neuro-Oncology Annual Scientific Meeting HOUSTON, Oct. 10, 2018 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of...